A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

This study is testing whether adding ramucirumab (a drug that blocks tumor blood vessel growth) to lorlatinib (a targeted therapy) can improve outcomes in patients with non-small cell lung cancer (NSCLC) that has an ALK gene rearrangement — a specific mutation that drives cancer growth. **You may be eligible if:** - You are over 18 years old - You have metastatic or recurrent NSCLC with a confirmed ALK gene rearrangement - You have at least one measurable tumor on imaging - You are in generally good health (Karnofsky score 70% or higher) - You are either treatment-naive in the metastatic setting (Cohort 1) or have progressed on at least one second-generation ALK inhibitor (Cohort 2) **You may NOT be eligible if:** - You have active or uncontrolled brain metastases - You have significant bleeding problems or recent blood clots - Your organ function (kidney, liver, blood) does not meet the required levels - You have not recovered from side effects of prior cancer treatments Talk to your doctor to see if this trial is right for you.